Table 1 Baseline demographic, clinical, and laboratory profiles based on the development of hepatic decompensation during follow-up
From: Serum liver fibrosis markers predict hepatic decompensation in compensated cirrhosis
Variable | Overall (n = 688) | No decompensation (n = 619) | Decompensation (n = 69) | P value |
|---|---|---|---|---|
Age (years) | 52.0 (41.0–59.0) | 51.0 (40.0–58.0) | 55.0 (49.0–62.0) | < 0.001 |
Males, n (%) | 412 (59.9) | 374 (60.4) | 38 (55.1) | 0.390 |
Etiology of cirrhosis, n (%) | Â | Â | Â | 0.001 |
 Hepatitis B | 486 (70.6) | 451 (72.9) | 35 (50.7) |  |
 Hepatitis C | 95 (13.8) | 83 (13.4) | 12 (17.4) |  |
 Autoimmune | 33 (4.8) | 29 (4.7) | 4 (5.8) |  |
 Alcohol | 22 (3.2) | 15 (2.4) | 7 (10.1) |  |
 Others | 52 (7.6) | 41 (6.6) | 11 (15.9) |  |
Esophageal varices, n (%) |  |  |  | < 0.001 |
 None | 409 (59.4) | 396 (64.0) | 14 (20.3) |  |
 Small | 279 (40.6) | 223 (36.0) | 55 (79.7) |  |
ALT (U/L) | 45.0 (24.0-109.0) | 46.0 (24.0-116.0) | 31.0 (21.0–60.0) | 0.007 |
AST (U/L) | 42.0 (26.0–90.0) | 43.0 (25.0–96.0) | 39.0 (28.5–66.0) | 0.656 |
ALP (U/L) | 77.0 (60.0-101.8) | 75.0 (59.0–98.0) | 93.0 (73.5–119.0) | < 0.001 |
GGT (U/L) | 59.0 (32.0-120.8) | 57.0 (31.0-117.0) | 76.0 (42.0-178.5) | 0.014 |
ALB (g/L) | 43.0 (39.1–46.2) | 43.3 (39.5–46.4) | 39.6 (36.0-42.6) | < 0.001 |
TBIL (μmol/L) | 17.4 (13.3–24.4) | 17.2 (13.2–23.8) | 19.2 (13.9–33.0) | 0.018 |
Cr (μmol/L) | 59.5 (50.0–70.0) | 60.0 (51.0–70.0) | 54.0 (47.0-64.5) | 0.012 |
INR | 1.06 (1.00-1.15) | 1.06 (1.00-1.14) | 1.14 (1.05–1.31) | < 0.001 |
PLT (×109/L) | 133.0 (96.0-172.0) | 140.0 (102.0-176.0) | 87.0 (56.5-114.5) | < 0.001 |
MELD score | 7.0 (6.0–9.0) | 7.0 (6.0–9.0) | 8.0 (7.0–11.0) | < 0.001 |
APRI | 0.94 (0.48–2.12) | 0.89 (0.46–2.05) | 1.42 (0.85–2.44) | 0.003 |
FIB-4 index | 2.72 (1.54–4.97) | 2.48 (1.47–4.65) | 4.61 (3.49–7.79) | < 0.001 |
Serum liver fibrosis markers | Â | Â | Â | Â |
 HA (ng/mL) | 134.5 (93.0-295.3) | 127.0 (93.0-271.0) | 257.0 (122.0-459.5) | < 0.001 |
 LN (ng/mL) | 95.0 (85.0-116.0) | 94.0 (84.0-110.0) | 112.0 (92.5-165.5) | < 0.001 |
 CIV (ng/mL) | 72.0 (62.0-133.0) | 69.0 (62.0-125.0) | 138.0 (83.5–199.0) | < 0.001 |
 PIIINP (ng/mL) | 9.7 (7.0–14.0) | 9.7 (7.0–14.0) | 11.0 (8.4–16.0) | 0.077 |
Length of follow-up (months) | 22.0 (13.0–32.0) | 22.0 (13.0–31.0) | 20.0 (10.5–35.5) | 0.705 |
hepatic decompensation, n (%) | 69 (10.0) | Â | Â | Â |
 Ascites, n (%) | 56 (8.1) |  |  |  |
 Variceal bleeding, n (%) | 27 (3.9) |  |  |  |
 Hepatic encephalopathy, n (%) | 14 (2.0) |  |  |  |